Skip to main content
Caplight Logo









Rejuvenate Biomed

Rejuvenate Biomed

Private
DiepenbeekHealthcare & Life Scienceshttps://www.rejuvenatebiomed.com/en

Last Round

Series B

Oct 12, 2021

Total Funding Raised

$23.11M

Company Overview

Rejuvenate Biomed is a biotechnology company that develops combination drugs to treat age-related diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Medical AI

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Application

Keywords

combination drugsage-related diseaselongevity biotechAI drug discoverysarcopeniadrug repurposingdrug discovery platformclinical stage biotechgerosciencein silico discoverynetwork biologyin vivo screeningC. elegans screeningsmall molecules

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Rejuvenate Biomed Comparables

Compare Rejuvenate Biomed with similar companies based on industry and business-model similarity.

Rejuvenate Biomed comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Biophytis SA
82%
BioAge Labs
76%
Epirium Bio
71%

Rejuvenate Biomed Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BOct 12, 2021
Series AMar 2, 2021
GrantAug 10, 2018
AcceleratorMar 1, 2018
SeedNov 1, 2017

Key People

Founding team and executive leadership

Ann Belien

Founder and CEO

Founding Team

Lizzy-Anne Neven

Chief Financial Officer

Executive Team

Rejuvenate Biomed Investors

Notable investors and investment history

Rejuvenate Biomed investors
InvestorRounds
Vesalius Biocapital PartnersSeries B
VLAIOSeries A, Grant
Johnson & Johnson Innovation - JLABSAccelerator

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 20, 2026

    Monthly visitors increased 745% MoM.

  • Mar 2, 2021

    Raised $3.84M led by Vesalius BioCapital.

Rejuvenate Biomed Filings

Explore SEC and related filing metadata, where available.

Rejuvenate Biomed filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Rejuvenate Biomed's valuation, stock price, and market status.

Is Rejuvenate Biomed a public or private company?

Rejuvenate Biomed is a private company.

What is the current stock price of Rejuvenate Biomed?

Rejuvenate Biomed is a private company with no public stock price. No recent secondary market data is available.

How much is Rejuvenate Biomed worth (valuation)?

Valuation information for Rejuvenate Biomed is not publicly available.

Can I buy Rejuvenate Biomed stock?

Rejuvenate Biomed shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Rejuvenate Biomed's last funding round?

Rejuvenate Biomed's most recent funding round was Series B on October 12, 2021.

Who are the main investors in Rejuvenate Biomed?

Key investors in Rejuvenate Biomed include Vesalius Biocapital Partners.

Will Rejuvenate Biomed IPO soon?

No public IPO plans have been announced for Rejuvenate Biomed.

How can I track Rejuvenate Biomed secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Rejuvenate Biomed's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersDiepenbeek
Employee Range15
Year Founded2017
Last FundingOct 12, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?